摘要
目的:分析氨溴索联合注射用头孢哌酮钠舒巴坦钠治疗新生儿感染性肺炎患儿的疗效。方法:回顾性分析2017年4月至2020年4月河南省直第三人民医院新生儿感染性肺炎患儿60例,将采用注射用头孢哌酮钠舒巴坦钠治疗的29例患儿作为对照组,将采用氨溴索静脉滴注、雾化吸入交替进行,同时,联合静脉注射头孢哌酮钠舒巴坦钠治疗的31例患儿作为观察组。对比两组疗效、临床症状改善时间,统计两组治疗前后血清炎性因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)、核因子-κB(NF-κB)]、心肌酶谱(肌酸激酶、乳酸脱氢酶)变化。结果:观察组总有效率93.55%(29/31)较对照组72.41%(21/29)高(P<0.05);观察组发热、咳嗽、气喘、肺部啰音改善时间较对照组短(P<0.05);治疗后,观察组血清IL-6、CRP、NF-κB水平较对照组低(P<0.05);治疗后,观察组肌酸激酶、乳酸脱氢酶水平较对照组低(P<0.05)。结论:氨溴索联合注射用头孢哌酮钠舒巴坦钠治疗新生儿感染性肺炎患儿效果显著,可减轻炎症反应,调节心肌酶谱参数,加快患儿症状改善,值得临床推广应用。
Objective:To analyze the efficacy of ambroxol combined with cefoperazone sodium and sulbactam sodium for injection in the treatment of neonatal infectious pneumonia.Methods:60 cases of neonatal infectious pneumonia in the Third People's Hospital of Henan Province from April 2017 to April 2020 were retrospectively analyzed.29 cases treated with cefoperazone sodium and sulbactam sodium for injection were selected as the control group,and 31 cases treated with ambroxol combined with cefoperazone sodium and sulbactam sodium for injection as the observation group.The curative effect and improvement time of clinical symptoms were compared between the two groups.The changes of serum inflammatory factors(IL-6,CRP,NF-κB)and myocardial enzymes(creatine kinase and lactate dehydrogenase)before and after treatment were statistically analyzed.Results:The total effective rate of the observation group was 93.55%(29/31)higher than that of the control group 72.41%(21/29)(P<0.05);the improvement time of fever,cough,asthma and lung rales in the observation group was shorter than that in the control group(P<0.05);after treatment,the serum levels of IL-6,CRP and NF-κB in the study group were lower than those in the control group(P<0.05);after treatment,the levels of creatine kinase and lactate dehydrogenase in the observation group were lower than those in the control group(P<0.05).Conclusion:Ambroxol combined with cefoperazone sodium and sulbactam sodium for injection has a significant effect in the treatment of neonatal infectious pneumonia,which can reduce the inflammatory reaction,regulate the parameters of myocardial enzyme spectrum,and accelerate the improvement of symptoms in children,which is worthy of clinical application.
作者
王连亮
张伟立
WANG Lianliang;ZHANG Weili(The Third People's Hospital of Henan Province,Zhengzhou Henan 450006,China)
出处
《药品评价》
CAS
2021年第2期88-91,共4页
Drug Evaluation
关键词
传染病
肺炎
感染性肺炎
氨溴索
头孢哌酮钠舒巴坦钠
炎性因子
婴儿
Communicable diseases
Pneumonia
Infectious pneumonia
Ambroxol
Cefoperazone sodium and sulbactam sodium
Inflammatory factor
Baby
